Phase 2 LEAP-005 Study Yields Promising Results Among Multiple GI Cancer Types
The combination therapy of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) produced positive antitumor outcomes in previously treated patients with advanced gastric cancer, advanced or metastatic microsatellite instability–high (MSI-H) or mismatch repair (MMR)– deficient colorectal cancer, and advanced biliary tract cancer, according to results presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
The phase 2 LEAP-005 trial (NCT03797326), which aimed to evaluate the safety and efficacy of the lenvatinib/pembrolizumab combination across a number of different solid tumor types, enrolled patients in 7 different cohorts. Only data specific to 3 gastrointestinal cancer types were presented at
Gastric Cancer Cohort Results
The gastric cancer cohort1…